Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
09/2003
09/18/2003WO2003075922A1 Nitrogen monoxide synthase inhibitors
09/18/2003WO2003075921A2 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
09/18/2003WO2003075917A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers
09/18/2003WO2003075915A1 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}- phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
09/18/2003WO2003075907A2 Small molecule entry inhibitors
09/18/2003WO2003075899A2 Combinations comprising epothilone derivatives and alkylating agents
09/18/2003WO2003075895A1 Tasted masked veterinary solid compositions
09/18/2003WO2003075888A2 Materials containing multiple layers of vesicles
09/18/2003WO2003075857A2 Amino-methyl substituted tetracycline compounds
09/18/2003WO2003075856A2 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
09/18/2003WO2003075850A2 Methods for alzheimer's disease treatment and cognitive enhancement
09/18/2003WO2003075846A2 Uses of monoclonal antibody 8h9
09/18/2003WO2003075844A2 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43
09/18/2003WO2003075840A2 Human antibodies specific to kdr and uses thereof
09/18/2003WO2003075839A2 Methods of inducing terminal differentiation
09/18/2003WO2003075836A2 Cathepsin cysteine protease inhibitors
09/18/2003WO2003075833A2 Screening method for orthopoxvirus antivirals
09/18/2003WO2003075741A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
09/18/2003WO2003075685A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
09/18/2003WO2003059283A3 Compounds for blocking androgen receptors
09/18/2003WO2003057163A3 Methods for preparing immunoconjugates
09/18/2003WO2003057130A3 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
09/18/2003WO2003053368A3 Chalcone derivatives and their use to treat diseases
09/18/2003WO2003051893A3 Improvements in pharmaceutical compositions
09/18/2003WO2003051838A3 Protein kinase inhibitors
09/18/2003WO2003051807A3 Improvements in pharmaceutical compositions
09/18/2003WO2003048122A3 Inhibitors of cytosolic phospholipase a2
09/18/2003WO2003037308A3 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion
09/18/2003WO2003035007A3 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
09/18/2003WO2003024489A3 Combination of a nsaid and a pde-4 inhibitor
09/18/2003WO2003024442A3 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
09/18/2003WO2003011851A3 Aromatic hydroxamic acid derivatives useful as hdac inhibitors
09/18/2003WO2003011274A3 Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
09/18/2003WO2003004628A3 Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme
09/18/2003WO2002102388A3 Active ingredient combination of e.g. galanthamine or deoxypeganine and e.g. acamprosate or memantine for treating an addiction such as alcoholism
09/18/2003WO2002095704A8 Use of nf-kappa-b inhibitors to treat dry eye disorders
09/18/2003WO2002083184A3 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
09/18/2003WO2002080982A3 Nucleic acid mucosal immunization
09/18/2003WO2002078627A3 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
09/18/2003WO2002077267A3 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
09/18/2003WO2002076925A3 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
09/18/2003WO2002059308A3 Method of diagnosing and treating cartilage disorders
09/18/2003WO2002050287A3 Multifunctional protease inhibitors and their use in treatment of disease
09/18/2003WO2002036110A9 Oral self-emulsifying formulations of pyranone protease inhibitors
09/18/2003WO2002011706A3 Drugs for sex dysfunctions
09/18/2003US20030176726 Selective retinoid agonists
09/18/2003US20030176701 Di-or triaza-spiro [4,5] decane derivatives
09/18/2003US20030176693 Diphenylalkylamine derivatives useful as opioid receptor agonists
09/18/2003US20030176678 Viricides, antitumor agents, antiproliferative agents, anticancer agents; genetic engineered Dna
09/18/2003US20030176670 Multivalent macrolide antibiotics
09/18/2003US20030176667 Transfroming growth factor; drug design
09/18/2003US20030176642 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
09/18/2003US20030176511 Compositions and methods for treating cardiovascular disorders
09/18/2003US20030176509 Methods and products related to 16-HETE analogs
09/18/2003US20030176506 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells
09/18/2003US20030176502 Pravastatin pharmaceutical formulations and methods of their use
09/18/2003US20030176501 For use in inhibiting HMG-CoA reductase; therapy and prophylaxis of hypercholesterolemia, atherosclerotic disease
09/18/2003US20030176497 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments
09/18/2003US20030176496 Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof
09/18/2003US20030176495 HIV Integrase inhibitors
09/18/2003US20030176489 Glyt-1 inhibitors
09/18/2003US20030176487 For therapy and prophylaxis of disorders related to unregulated tyrosine kinase signal transduction, including cell proliferative and metabolic disorders
09/18/2003US20030176486 For use as an inhibitor of lipopolysaccharides (LPS)
09/18/2003US20030176484 Administering to the mammal an effective amount of a GSK-3 beta (glycogen synthase kinase-3 beta) to promote bone formation and treat bone metabolic diseases such as osteoporosis
09/18/2003US20030176482 Imidazole derivatives or their salts
09/18/2003US20030176481 Novel imidazole derivatives with anti-inflammatory activity
09/18/2003US20030176479 Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
09/18/2003US20030176476 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
09/18/2003US20030176475 For therapy of disorders of the gastrointestinal system, and of the central nervous system
09/18/2003US20030176465 Cyclic amino acid derivatives
09/18/2003US20030176463 For therapy of disease states resulting from angiogenesis; can be administered orally
09/18/2003US20030176460 Piperidine compounds for use as ccr-3 inhibitors
09/18/2003US20030176455 Inhibiting cell death following cellular regeneration in a mammal in need thereof, which comprises providing with an effective amount of a rapamycin
09/18/2003US20030176454 N-coating heterocyclic compounds
09/18/2003US20030176453 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/18/2003US20030176451 Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound
09/18/2003US20030176449 For therapy and prophylaxis of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders
09/18/2003US20030176448 Mitochondria protecting agents for treating mitochondria associated diseases
09/18/2003US20030176445 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists
09/18/2003US20030176444 For therapy of inflammation
09/18/2003US20030176441 Inhibitsthe binding of eotaxin to the CCR-3 receptor and thereby provide a means of combating eosinophil induced diseases, such as asthma
09/18/2003US20030176438 Useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer; as inhibitors of checkpoint kinase Cds1 (in man also known as Chk2)
09/18/2003US20030176433 For therapy and prophylaxis of hepatitis C virus (HCV) infection
09/18/2003US20030176432 Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids
09/18/2003US20030176430 For therapy and prophylaxis of Tachykinin-mediated diseases
09/18/2003US20030176429 2-thio-4h-3,1-benzoxazin-4-one derivatives for use as enzyme inhibitors
09/18/2003US20030176425 Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
09/18/2003US20030176420 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists
09/18/2003US20030176419 As inhibitors of the retinoic acid-metabolism, as drugs
09/18/2003US20030176418 For therapy of Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age- related cognitive decline
09/18/2003US20030176416 For therapy of disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors
09/18/2003US20030176415 1,2,3,4-tetrahydroisoquinoline derivatives
09/18/2003US20030176413 Polycyclic guanine derivative phosphodiesterase V inhibitors
09/18/2003US20030176405 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
09/18/2003US20030176403 Combination chemotherapy
09/18/2003US20030176401 Sodium salt of an azo derivative of 5-aminosalicylic acid
09/18/2003US20030176392 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes ("KHSV")
09/18/2003US20030176390 Methods of treating insulin resistance syndrome and diabetes
09/18/2003US20030176388 Fatty acid synthase mRNA binding protein
09/18/2003US20030176383 Antisense modulation of p38 mitogen activated protein kinase expression
1 ... 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 ... 1564